Takeda partners with Insilico in $600M AI drug discovery deal

Takeda has partnered with Hong Kong-based Insilico Medicine to leverage artificial intelligence for early-stage drug discovery across its therapeutic portfolios.

Specific therapeutic areas or disease targets were not disclosed. The partnership grants Takeda access to Insilico’s Pharma.AI platform, facilitating biological target identification, molecular design, and clinical trial prediction.

The collaboration aims to identify drug candidates meeting predefined scientific and early development criteria. Insilico will lead AI-driven discovery, while Takeda will advance selected candidates through clinical development.

Deal value and development rights

Takeda secures exclusive worldwide rights to develop, manufacture, and commercialise novel therapeutics identified through this partnership.

Insilico reported approximately US$60 million in project initiation fees, near-term payments, and milestones. The total deal value could reach US$600 million upon achieving preclinical, clinical, commercial, and sales milestones.

Additional payments are contingent on preclinical, clinical, commercial, and sales milestones. Insilico is also eligible for tiered royalties on future sales.

Insilico founder and CEO Alex Zhavoronkov stated that proceeds will support early-stage research under the collaboration. He noted that later-stage timelines depend on Takeda’s clinical activities and coordinated efforts from both companies.

AI drug discovery partnerships

The Pharma.AI suite includes tools for target discovery, molecule generation, and clinical development prediction. The platform features PandaOmics for target discovery, Chemistry42 for de novo small-molecule generation, and InClinico for forecasting clinical trial transition probability.

Insilico has advanced its own AI-generated drug candidate, Rentosertib (formerly ISM001-055 or INS001-055), into clinical testing. This small-molecule TNIK inhibitor for idiopathic pulmonary fibrosis was evaluated in a Phase 2a randomised clinical trial.

Chris Arendt, Takeda’s chief scientific officer and head of research, highlighted that the agreement combines Takeda’s disease biology expertise with Insilico’s AI capabilities. He added that Takeda is integrating automation, robotics, and generative AI into its discovery processes.

This follows another AI drug-discovery deal by Takeda earlier this year. In February, Takeda entered a multi-year collaboration with Iambic, valued at over US$1.7 billion, to use AI for designing small-molecule drugs for cancer and gastrointestinal diseases.

Iambic’s platform includes NeuralPLexer, an AI model predicting how drug molecules bind to proteins.

According to data cited by the South China Morning Post from China’s National Medical Products Administration, Chinese drugmakers signed 157 out-licensing deals worth US$135.7 billion in 2025.

Under the Takeda–Insilico agreement, Takeda receives exclusive worldwide rights to candidates discovered via Insilico’s platform. Insilico stated it has signed collaboration agreements with a combined potential value exceeding US$7 billion since the start of the year.

Last month, Insilico announced a collaboration with South Korea’s SK Biopharmaceuticals focusing on neuroimmune disorders. This agreement includes up to US$18 million in upfront and near-term milestone payments, with a total potential value of over US$2.5 billion.

In March, Eli Lilly expanded its collaboration with Insilico in an AI-powered drug discovery deal worth up to US$2.75 billion. The agreement granted Lilly exclusive worldwide rights to develop, manufacture, and commercialise certain oral treatments in preclinical development.

Insilico’s Hong Kong-listed shares rose 13.5% following the announcement of the Takeda agreement.

See also: NVIDIA BioNeMo accelerates Anthropic Claude Science

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and is co-located with other leading technology events including the Cyber Security & Cloud Expo. Click here for more information.

AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.